The IRF2 Knockout NCI-H1975 Polyclonal Cells product provides a polyclonal population of NCI-H1975 human lung adenocarcinoma epithelial cells engineered by CRISPR/Cas9-mediated gene disruption of the interferon regulatory factor 2 (IRF2) locus. This pooled knockout format yields a heterogeneous loss-of-function model that avoids the clonal bias inherent to isolated cell lines, making it well-suited for robust and reproducible investigations of IRF2-dependent processes. The product is designed for professional researchers studying interferon signaling, cell cycle regulation, apoptosis, and cancer biology.
NCI-H1975 is a widely used non-small cell lung cancer (NSCLC) cell line derived from a lung adenocarcinoma. It carries clinically relevant activating mutations in EGFR (L858R) and PIK3CA, which drive constitutive proliferation and survival signaling. These genetic features make the line particularly valuable for exploring EGFR-targeted therapies and PI3K pathway signaling. The epithelial origin of NCI-H1975 retains key characteristics of lung adenocarcinoma, providing a relevant cellular context for functional studies.
IRF2 is a dual-function transcription factor that predominantly acts as a repressor but can also activate gene expression. It is a central modulator of the interferon response, where it competes with IRF1 for binding to interferon-stimulated response elements (ISREs). Upstream, IRF2 expression is induced by type I and type II interferons through the JAK-STAT pathway, involving IFNAR1/2 engagement, activation of JAK1 and TYK2, and phosphorylation of STAT1 and STAT2. IRF2 interacts with transcriptional coactivators such as p300/CBP and corepressors including HDAC1, and it regulates downstream targets like the cyclin-dependent kinase inhibitor p21/CDKN1A, tumor suppressor p53/TP53, apoptosis effector Caspase-8/CASP8, anti-apoptotic Bcl-2, and interferon-stimulated genes (ISGs) such as OAS1 and MX1. This network places IRF2 at a critical intersection of interferon signaling, cell cycle control, and apoptotic regulation.
Disrupting IRF2 in the NCI-H1975 background disrupts the balance of transcriptional regulation within interferon and apoptotic networks. The loss of IRF2-mediated repression is expected to alleviate suppression of tumor suppressors like p53 and p21, potentially restoring cell cycle checkpoints and apoptotic sensitivity. Given the EGFR and PIK3CA mutations, IRF2 depletion may alter cell proliferation and drug sensitivity profiles, making this polyclonal knockout model a powerful tool for dissecting the interplay between oncogenic drivers and interferon regulatory circuits. The model enables examination of how IRF2 loss affects cellular responses to interferon stimulation, chemotherapeutic agents, and targeted inhibitors in a genetically defined NSCLC context.
This product is well-suited for a spectrum of experimental applications. Researchers can employ the polyclonal knockout cells in Western blotting and RT-qPCR to confirm IRF2 disruption and analyze expression changes of downstream effectors like p21 and Caspase-8. RNA-seq can provide global transcriptional fingerprints of interferon-responsive gene programs. Functional studies including apoptosis assays and cell cycle analysis by flow cytometry elucidate IRF2??s role in cell death and proliferation. Drug sensitivity screens with EGFR tyrosine kinase inhibitors or PI3K pathway inhibitors assess IRF2??s influence on therapeutic response. Co-immunoprecipitation experiments may probe IRF2 interactions with STAT1 or p300. Additionally, the model supports immune evasion and viral infection studies. For further details or custom inquiries, please contact Ascent Research.
